In 2023, the FDA banned 19 peptides from compounding pharmacies. No specific safety incident. No clear signal. Just a regulatory decision that pushed millions of patients toward gray market suppliers and overseas Clinical spectrum and evolution of immune checkpoint inhibitors toxicities over a decadea worldwide perspective eClinicalMedicine Adverse Event Reporting in Clinical Trials Population Scale Identification of Differential Adverse Events Before and During a Pandemic Zitnik Lab Adverse Event Research Integrity & Compliance Montana State University The Irish National Adverse Event Study 2 (INAES 2): longitudinal trends in adverse event rates in the Irish healthcare system BMJ Quality & Safety